Intellia, Thank Regeneron validate such were by VelociGene, those Velocimmune others. to to efficiently you, the with collaborative as of will that our quickly through Len. our us and technologies which internally Bluebird overview whether allow I therapeutic turnkey targets capabilities, our and such and Alnylam, is possible and identify solutions, foundational diverse go Center provide rapidly genetic made pipeline, important new an approaches developed Genetic as and
the diabetic PANORAMA This showed Palmer Meeting, nonproliferative for two complications. weekend in Starting with market present the EYLEA. which year at in Baskin of data risk developing Angiogenesis vision-threatening the reduction we study retinopathy, will a the
closely II AMD that wet safety begin the we in clinical initial followed EYLEA, in provide discuss will III mid-year time trial same a high-dose wet rationale by of and Phase efficacy testing the a trial III AMD. in Phase in for DME study will data. A At Phase will currently
Moving asthma, which diseases of interleukin-X is pathways, on of many since blocker from than allergic globally atopic lives as with so XXX,XXX such Dupixent, our dermatitis and changing the both nasal the to suffering rhinosinusitis more patients and dual treated launch. people polyps interleukin-XX chronic with
to FDA severe of XX XXXX. PDUFA Just a May announced moderate six last extend atopic date the review a priority to undertaking week, that Dupixent years aged target of suffering approval XX, to we from with to dermatitis children is
We approval will continue that indicated and efficacy the will this children. to would hope for this reflect safety approved, profile If be Dupixent. first the biologic these remarkable of
which the are seen As box and black evidenced of with infection inhibitors. serious by absence kinase associates neuromodulatory any biologics or often a warning other risks
While long-term near increasingly update on underdiagnosed opportunities treatment is EOE performance, would with Marion will recognized Dupixent. allergic but you effective and Eosinophilic or esophagitis a to highlight serious quarterly options. I for other like currently limited condition
Following III we up II/III portion study will out Phase promising Phase our by to read and while continues II the on of the in enroll. adolescents mid-year portion study, proof-of-concept on adults our Phase
year. a studying in patients study Phase are the second we EOE of half the Additionally, in pediatric III
therapies related patients Palforzia, allergic food But oral front, recent still the a and We Palforzia further approval these the peanut at an allergy. as many in Dupixent for combination about EOE think outcomes immunotherapy conditions. need potential for improve collaborator for are is has these patients. study of risk to treatment the other allergies, with for we an On our of are for there Aimmune’s excited enormous for
are also am new this bronchopulmonary have already to will last chronic commence November pleased the I pivotal half spontaneous the share for studies for in Dupixent aspergillosis in the off. started. first study nodularis urticaria, bullous prurigo kicking in Studies we The and of year. announced indications allergic pemphigoid
let’s the to many immuno-oncology, currently few and a Now patients positioned that today. benefits to are immunotherapy strategically and are moments compete, more we turn of extend benefiting enhance spend where on
With alone. responsiveness we Libtayo more our for derived the an other respond the in do opportunity and half that antibodies antibodies, therapy the to Libtayo, with including compete VelociGene than we bispecific treatment PD-X from are have looking Combining toolkit important Velocimmune not to enhance landscape. PD-X patients to
with such which very checkpoint breast, show as to the point. Moreover this our such at have extend patients to inhibition combinations pancreatic prostate potential and reach response limited colon, to cancers
addition in this cancer. Later foundational milestones. being to the assessing data near-term overall year pivotal in approach some cell expecting Libtayo are our lung committee to non-small For we will combinatorial the survival monitoring Libtayo in interim study independent analysis oncology, monotherapy for pre-specified conduct
Libtayo that the response objective confirmed as XXX XX% last announced of determined investigators was for randomized patients, quarterly versus first by the update, XX% an interim we At the rate chemotherapy. for analysis
endpoint validated Libtayo for objective of this not profound cancer terms a in for is indicating activity in response promising regulatory Although, and setting. rate lung approval clinical
is tested which by in pivotal Libtayo study to is than lung cancer enrolled other combination chemotherapy being with and fully midyear. expected more Our enroll in is XX%
While, investigating from available combination still cancers expand we than cancers, underserved we patient’s we melanoma therapy different with are approaches working skin benefit non-melanoma patients. where PD-X skin Libtayo the patients half treatment to remain believe less these with are alone, and options the for
skin advanced Libtayo PD-LX carcinoma of and of the to is that or approved with squamous a therapeutic remains other cell or inhibitors. in similar only profile group the safety PD-X the first that CSCC
as we recently registrational now Libtayo the study CSCC are promising recent study which setting, follow-up with in a study. CSCC well as neoadjuvant a on Following adjuvant results in neoadjuvant announced, enrolling we
proceed We of year. the hoping this are positive to in pivotal looking also basal readout the we mid-XXXX. cell for forward the carcinoma data are potentially skin the regulatory data If are filing to with
exciting that the The platform. and these with a tumor T-cell a meetings Hematology designed to we data Society killer And cell from signal ASH the CDX leading progress we antibodies. make activation the first our to antibody of of to tumor class our bring continue destruction. or in trigger one T-cell American to bispecifics presented are so-called process bispecific At
complete bispecific, CAR-T in we B-cell all XX% patients. X REGNXXXX XX% overall rates XX follicular CDXXxCDX For response large we reported diffuse late-stage complete rates response overall lymphoma with in rates XX naive were which In response lymphoma late-stage observed of patients. our responses
program to saw quite promising this including subtypes. supports for pivotal monotherapy several failed who overall in these bispecific II single therapy a potentially agent other complete follicular REGNXXXX as has several lymphoma clinical Clearly CAR-T XX% REGNXXXX. of initiation demonstrated response as rates DLBCL studies well patients and a and in achieving relapsed/refractory remarkably, with treatment lymphoma, non-Hodgkin's with patients in had Phase relapsed/refractory activity response of Moreover we patients a XX X late-stage
also earlier of planning initiate non-Hodgkin's year lines lymphoma. combination chemotherapy studies to are in this We
to REGNXXXX, show bispecific in safety patient first able of in ASH the same this At presented program for bispecific. the we our the dosed same our Remarkably beginning meeting initial year. late-stage preliminary data the and later second was myeloma. meeting at and ASH BCMAxCDX at efficacy the we CDX XXXX data multiple were
In which the doses, patients, median very higher all of four of of in therapy, of negativity. These failed observed of responses achieved systemic MRD anti-CDXX. the objective out were two a prior lines patients were had advanced seven who initial including three two
enrolling dose currently escalation are higher cohorts. We
also mediated cell costim known inventory we T-cells. bispecifics year, or killing referred bispecifics. of This that These novel to bispecifics second two activate clinic. costim into signal the as also CDXX record optimize signal advanced CDXX Because are they normally as our is to by class the
toxicity. cytokine pathway Researchers T-cells to the since CDXX indiscriminately in clinical this which storm superagonist, of and almost activated for ever the disastrous activation have years bodies involving avoided volunteers severe T-cell trial targeting leading healthy XX
In contrast, engaging tumor our this site. bispecifics T-cells to locally problem are at CDXX only the designed avoid by
with validated synergistic studies, with demonstrated which a or to other published were preclinical historically blockade. bispecifics Libtayo activity for science when ago few As which medicine, translational our tumors costims of in combined some were and unresponsive PD-X by even weeks
Libtayo of last in year, of the PSMAxCDXX the patients. advanced our trial our enrolled patients with prostate first first cancer in At end clinical costim in we combination
expect We the in to XXXX. costims clinic additional enter in
the Now our move I'd to of to pipeline. on like rest
convenient form. the blocker, to and blockade available self-administered this to more subcutaneous the achieve with do compared inappropriate therapies With CX pozelimab, of currently complement complete dosage activation is to our a more goal a
biomarker an of in subcutaneous a X hemoglobinuria levels nocturnal paroxysmal patients blood study eight. damage, from initial in for at Phase normal Results showed that regimen, dehydrogenase, announced cell six-patient red pozelimab weekly the week December, maintained our at our cohort lactate
further novel combining to are - test potential five which anti dosing partner approach frequency. the pozelimab maximize significantly we positioned with siRNA, to CX Alnylam's has anti while Importantly, efficacy, reducing by a uniquely our
This series opportunities our will be combination of for with the of antibodies first in siRNA. a
our combinations siRNA will well potentially We be with pivotal pozelimab initiating program as with year. this the as
by with year on line Phase disease are update bodies top few traps orphan programs. in Earlier to X our provide progressively a often a in Activin ligaments bone, a antibody them late-stage of fibrodysplasia tendons muscles, leading to like and ossificans A progressive, an second other own replaced that study for forming I’d patient's results skeleton which their devastating this asphyxiation. of the Garetosmab,
In a compared lesions disease. the reduction in transform nearly well the potential data XX treatment placebo. pediatric in study the plan has of to a XX% with as discuss patient to This this formation initiate Garetosmab as new demonstrated bone study, course of the the regulators, to patients. We
In we for for homozygous submission patients. regulatory hypercholesterolemia our also antibody are XXXX, planning a familial ANGPTLX evinacumab,
safety studies also fasinumab or anticipating the comparing readout are We as NSAIDs. to osteoarthritis and including as anti-NGF the in it naproxen pain long-term X of Phase studies study, well
response Part the the partnership Services. address capabilities we Together, with our emerging and Finally, office rapid of Human Department I’d exploit and outbreaks. response Health like our to preparedness discussing to hope to infectious disease finish BARDA. of by of to
initially the the MERS a and to MERS We global coronavirus public that's built is emergency. current work virus with health program the XXXX BARDA Wuhan causing this related address to epidemic. closely
response for of an recently cocktail. England Health Organization, and Medicine BARDA for our New the potential was the just antibody together rapid therapeutic progressing to even candidates published on working submission the and as with in patients cure in and in we focus capabilities months the Journal XXXX, our for of life-saving Then World six in turned to approval ongoing allowing resulting Ebola FDA Ebola rolling sickest
are week, collaboration Wuhan address this extending the with just our we now announced to BARDA them As coronavirus.
of new thereafter. well set available for use as could soon potential compassion already treatments treatments scaling set or testing be patients as within of up could antibody one few We’re that be available for that in months, a a
call Marion. I With will turn over that, the to
